FDA might withhold review of Biodel's VIAject insulin

08/24/2010 | Reuters

Review of Biodel's new-drug application for diabetes treatment VIAject might be withheld after the FDA warned of possible violations at a Burlington, Vt., plant that makes the vials of insulin. The agency issued the warning letter to Albany Molecular Research, which operates the manufacturing site.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA